Stem Cell Therapeutics Corp. (TSX-V: SSS), a Toronto-based biopharmaceutical development company, is Canada’s sole publicly-traded firm focused on progressing cancer stem cell breakthroughs into new and innovative cancer treatments. With a foundation of over 50 years of pioneering Canadian stem cell research, the company benefits from strong connections to several Toronto academic institutes and oncology treatment centers, forming one of the world's most prestigious cancer research hubs. Stem Cell Therapeutics Corp. was founded in 2004 and operates within the biopharma and biotechnology industries. The company's last investment of $33.00M was in Post-IPO Equity on 16 December 2013. The investment was made by Ridgeback Capital, VenBio Partners, Sabby Capital, Special Situations Funds, HSMR Advisors, and Merlin Nexus.
No recent news or press coverage available for Stem Cell Therapeutics.